Louis Denis

Company: Verastem. inc

Job title: Chief Medical Officer

Seminars:

Clinical Development of RAF/MEK clamp VS-6766; Breakthrough Designation & Beyond 5:00 pm

RAF/MEK clamp VS-6766 and FAK inhibitor defactinib are in clinical development in RAS/MAPK driven cancers Clinical experience and progress in recurrent low-grade serous ovarian cancer (LGSOC) and KRAS mutant NSCLC will be presented Future directions will be discussed – including clinical trials in new indications and combination treatment approachesRead more

day: Day One Track I